gettyAmid a frenzy for AI-related stocks, shares of a little-known biotech company in South Korea got an Nvidia-esque boost. Alteogen, a pharmaceutical company with nothing to do with AI, saw its share price jump about 25% Friday to an all-time high after it announced a licensing deal with drug giant Merck. The stock surge has made Park Soon-jae, the company’s founder and CEO, South Korea’s newest billionaire.Park, who turns 70 in December, is the largest shareholder of Alteogen, with a 19.4% stake worth $1 ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as a monotherapy as adjuvant treatment, for the treatment of resectable non-small cell lung cancer (NSCLC) at high ris ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (carboplatin and paclitaxel), followed by KEYTRUDA as a single agent for the treatment of patients with primary advanced or recurrent endometrial carci ...

400tmax Since January 3, 2022, when the last stock market correction started, the Dow Jones Industrial Average (DJI) has outperformed all three other major equity indexes on a total return basis. Performance of 4 total return stock market indexes (Price Action Lab Blog - Norgate Data) Despite a gain of 55.1% for the NASDAQ-100 total return last year, the Dow is still ahead with a gain of 11.2% versus 10.4% for the tech stocks since the start of 2022, on a total return basis. The S&P 500 total return is 8.7% ...

As filed with the Securities and Exchange Commission on February 9, 2024 Registration No. 333-276817 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sunshine Biopharma, Inc. (Exact name of registrant as specified in its charter) | Colorado | 8731 | 20-5566275 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | ...

Merck’s (MRK) Animal Health unit, known as Merck Animal Health, announced that it has entered into an agreement with Elanco Animal Health Incorporated (ELAN) to acquire the latter’s aqua business for $1.3 billion in cash.The acquisition of Elanco Animal Health’s aqua business will add an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species, two related aqua manufacturing facilities in Canada and Vietnam, and a research facility in Chile to Merck’s Animal Health bu ...

Veteran healthcare company Merck (MRK 4.64%) was looking very healthy on the stock market Thursday. Its shares gained 4.6% in value across the day, following the publication of quarterly results that featured a surprise on the bottom line. That gain was notably higher than the 1.3% advance recorded by the S&P 500 index.Fourth-quarter results were published, and...Before market open, Merck took the wraps off both its fourth quarter and full-year 2023 results.For the former period, the global company's total ...

Key TakeawaysMerck & Co. on Thursday reported a surprise adjusted profit for the fourth quarter as sales of its Keytruda cancer drug and Gardasil HPV vaccine soared.The pharmaceutical firm predicted better-than-expected full-year earnings per share.The news sent Merck shares to an all-time high in intraday trading Thursday.Merck & Co. (MRK) shares traded at an all-time high Thursday after the pharmaceutical company posted a surprisingly positive adjusted profit after sales jumped for its cancer drugs and va ...

Merck (MRK) reported adjusted earnings of 3 cents per share in fourth-quarter 2023, wider than the Zacks Consensus Estimate of a loss of 9 cents. In the year-ago period, the company reported adjusted earnings of $1.62. The downside was due to a one-time charge incurred by the company for a collaboration with Daiichi Sankyo, entered in October.Including acquisition and divestiture-related costs, restructuring costs, income and losses from investments in equity securities and certain other items, loss per sha ...

Merck Q4 2023 Earnings Agenda ...